Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Miranda Murray, Deanna Kerrigan, Krischan J. Hudson, Nicola Walters, Tahilin Sanchez Karver, Andrea Mantsios & Noya Galai. (2020) Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial. HIV Research & Clinical Practice 21:4, pages 105-113.
Read now
Read now
Brian Godman, Holly McCabe, Trudy D Leong, Debjani Mueller, Antony P. Martin, Iris Hoxha, Julius C. Mwita, Godfrey Mutashambara Rwegerera, Amos Massele, Juliana de Oliveira Costa, Renata Cristina Rezende Macedo do Nascimento, Livia Lovato Pires de Lemos, Konstantin Tachkov, Petya Milushewa, Okwen Patrick, Loveline Lum Niba, Ott Laius, Israel Sefah, Suhaj Abdulsalim, Fatemeh Soleymani, Anastasia N Guantai, Loice Achieng, Margaret Oluka, Arianit Jakupi, Konstantīns Logviss, Mohamed Azmi Hassali, Dan Kibuule, Francis Kalemeera, Mwangana Mubita, Joseph Fadare, Olayinka O. Ogunleye, Zikria Saleem, Shazhad Hussain, Tomasz Bochenek, Ileana Mardare, Alian A. Alrasheedy, Jurij Furst, Dominik Tomek, Vanda Markovic-Pekovic, Enos M. Rampamba, Abubakr Alfadl, Adefolarin A Amu, Zinhle Matsebula, Thuy Nguyen Thi Phuong, Binh Nguyen Thanh, Aubrey Chichonyi Kalungia, Trust Zaranyika, Nyasha Masuka, Ioana D. Olaru, Janney Wale, Ruaraidh Hill, Amanj Kurdi, Angela Timoney, Stephen Campbell & Johanna C. Meyer. (2020) Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Review of Pharmacoeconomics & Outcomes Research 20:1, pages 1-26.
Read now
Read now
Vania Giacomet, Maria V. Cossu, Amedeo F. Capetti, GianVincenzo Zuccotti & Giuliano Rizzardini. (2019) An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents. Expert Opinion on Pharmacotherapy 20:3, pages 269-276.
Read now
Read now
Nicolas A. Margot, Kathryn M. Kitrinos, Marshall Fordyce, Scott McCallister, Michael D. Miller & Christian Callebaut. (2016) Rare emergence of drug resistance in HIV-1 treatment -naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. HIV Clinical Trials 17:2, pages 78-87.
Read now
Read now
Ed L. Wilkins, Calvin J. Cohen, Benoit Trottier, Stefan Esser, Don E. Smith, Bernhard Haas, Cynthia Brinson, Will Garner, Susan Chuck, David Thorpe & Shampa De-Oertel. (2016) Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment. AIDS Care 28:3, pages 401-408.
Read now
Read now
Articles from other publishers (29)
Marisa Brizzi, Elizabeth M. Sherman, Sarah B. Green, Diana N. Nowicki, Emily N. Drwiega, Melanie R. Nicol, Daniel B. Chastain, Eric G. Sahloff, William R. Truong, David Cluck, Melissa E. Badowski, Sarah M. Michienzi & Spencer H. Durham. (2023)
Personalizing prevention: Advances in pharmacotherapy for
HIV
prevention
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 43:4, pages 305-320.
Crossref
Crossref
Vuyolwethu Khwaza, Buhle Buyana, Xhamla Nqoro, Sijongesonke Peter, Zintle Mbese, Zizo Feketshane, Sibusiso Alven & Blessing A. Aderibigbe. 2023. Viral Infections and Antiviral Therapies. Viral Infections and Antiviral Therapies
407
492
.
Gwang Suk Kim, Youngin Kim, Min Kyung Park, Sang A Lee, Youngjin Lee & Mi-So Shim. (2022) Barriers and facilitators on the HIV care continuum among adults living with HIV in high-income countries: a scoping review protocol. Systematic Reviews 11:1.
Crossref
Crossref
Katie A O'Connell, Shaheer Sherani, Alice Kisteneff, Karthik Bhat, Jarrett Slater, Christian F Klein, Brent Lavey, Ashlee Malone, Rehan Qayyum & Catherine J Derber. (2022) Factors Affecting Adherence With Follow-up Appointments in HIV Patients. Cureus.
Crossref
Crossref
Qiaosen Chen, Jun Liu, Xiaobing Fu, Fang Yang, Qicai Liu, Junbin Li, Zhimin Tan, Jing Li, Kaihao Lin, Yao Yan, Yi Yang, Yan Li & Hongbo Jiang. (2022) Effect of Late Testing and Antiretroviral Treatment on Mortality Among People Living With HIV in the Era of Treat-All in Guangdong Province, China, 1992–2018: A Cohort Study. Frontiers in Public Health 10.
Crossref
Crossref
Jacob Bor, Sheryl A Kluberg, Michael P LaValley, Denise Evans, Kamban Hirasen, Mhairi Maskew, Lawrence Long & Matthew P Fox. (2022) One Pill, Once a Day: Simplified Treatment Regimens and Retention in HIV Care. American Journal of Epidemiology 191:6, pages 999-1008.
Crossref
Crossref
Zhiguo Wang & Baofeng YangZhiguo Wang & Baofeng Yang. 2022. Polypharmacology. Polypharmacology
343
374
.
Xu-Sheng Huang, Rong-Hua Luo, Xiong-Lin Hu, Huan Chen, Si-Ying Xiang, Cheng-Run Tang, Chun-Tao Zhang, Xiao-Ning Shen & Yong-Tang Zheng. (2020) The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro. Current HIV Research 18:5, pages 332-341.
Crossref
Crossref
Xingbao Tao, Yanqiu Lu, Yihong Zhou, Lvlang Zhang & Yaokai Chen. (2020) Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials. International Journal of Infectious Diseases 93, pages 108-117.
Crossref
Crossref
H‐J Stellbrink, A Lazzarin, I Woolley & JM Llibre. (2020) The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single‐tablet regimen in the expanding spectrum of fixed‐dose combination therapy for HIV. HIV Medicine 21:S1, pages 3-16.
Crossref
Crossref
Mark S. Dworkin, Palak Panchal, Wayne Wiebel, Robert Garofalo, Jessica E. Haberer & Antonio Jimenez. (2019) A triaged real-time alert intervention to improve antiretroviral therapy adherence among young African American men who have sex with men living with HIV: focus group findings. BMC Public Health 19:1.
Crossref
Crossref
HB Krentz, S Campbell, M Lahl & MJ Gill. (2019) De‐simplifying single‐tablet antiretroviral treatments: uptake, risks and cost savings. HIV Medicine 20:3, pages 214-221.
Crossref
Crossref
Hannah A. Blair. (2018) Dolutegravir/Rilpivirine: A Review in HIV-1 Infection. Drugs 78:16, pages 1741-1750.
Crossref
Crossref
J Young, C Smith, R Teira, P Reiss, I Jarrín Vera, H Crane, JM Miro, A D'Arminio Monforte, M Saag, R Zangerle & HC Bucher. (2017)
Antiretroviral pill count and clinical outcomes in treatment‐naïve patients with
HIV
infection
. HIV Medicine 19:2, pages 132-142.
Crossref
Crossref
Judit Peñafiel, Elisa de Lazzari, Mireia Padilla, Jhon Rojas, Ana Gonzalez-Cordon, Jose L. Blanco, Jordi Blanch, Maria A. Marcos, Montserrat Lonca, Maria Martinez-Rebollar, Montserrat Laguno, Amparo Tricas, Ana Rodriguez, Josep Mallolas, Jose M. Gatell & Esteban Martinez. (2017) Tolerability of integrase inhibitors in a real-life setting. Journal of Antimicrobial Chemotherapy 72:6, pages 1752-1759.
Crossref
Crossref
Matt S. Anderson, Sauzanne Khalilieh, Ka Lai Yee, Rachael Liu, Li Fan, Matthew L. Rizk, Vedangi Shah, Azra Hussaini, Ivy Song, Lisa L. Ross & Joan R. Butterton. (2016) A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir. Clinical Pharmacokinetics 56:6, pages 661-669.
Crossref
Crossref
Laurent Cotte, Tristan Ferry, Pascal Pugliese, Marc-Antoine Valantin, Clotilde Allavena, André Cabié, Isabelle Poizot-Martin, David Rey, Claudine Duvivier, Antoine Cheret, Pierre Dellamonica, Pierre Pradat & Jean-Jacques Parienti. (2017) Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study. PLOS ONE 12:2, pages e0170661.
Crossref
Crossref
D. Armenia, D. Di Carlo, A. Calcagno, G. Vendemiati, F. Forbici, A. Bertoli, G. Berno, S. Carta, F. Continenza, V. Fedele, R. Bellagamba, S. Cicalini, A. Ammassari, R. Libertone, M. Zaccarelli, V. Ghisetti, M. Andreoni, F. Ceccherini-Silberstein, S. Bonora, G. Di Perri, A. Antinori, C. F. Perno & M. M. Santoro. (2016) Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. Journal of Antimicrobial Chemotherapy, pages dkw512.
Crossref
Crossref
Victor Musiime, Philip Kasirye, Bethany Naidoo-James, Patricia Nahirya-Ntege, Tawanda Mhute, Adrian Cook, Lincoln Mugarura, Marshall Munjoma, Navdeep K. Thoofer, Emmanuel Ndashimye, Immaculate Nankya, Moira J. Spyer, Margaret J. Thomason, Wendy Snowden, Diana M. Gibb & Ann Sarah Walker. (2016) Once vs twice-daily abacavir and lamivudine in African children. AIDS 30:11, pages 1761-1770.
Crossref
Crossref
Rosario Palacios, Marisa Mayorga, Isabel A. Pérez-Hernández, Antonio Rivero, Alfonso del Arco, Fernando Lozano & Jesús Santos. (2016) Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet. Journal of the International Association of Providers of AIDS Care (JIAPAC) 15:3, pages 189-193.
Crossref
Crossref
Dominique Salmon-Ceron. (2016) La fin du VIH peut-elle devenir une réalité ?. Bulletin de l'Académie Nationale de Médecine 200:4-5, pages 889-905.
Crossref
Crossref
Jing Hao, Rosa Rodriguez-Monguio & Enrique Seoane-Vazquez. (2015) Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals. PLOS ONE 10:10, pages e0140708.
Crossref
Crossref
Rebecca Scherzer & Michael G. Shlipak. (2015) Individual assessment of CKD risk in HIV-positive patients. Nature Reviews Nephrology 11:7, pages 392-393.
Crossref
Crossref
Jason Brunetta, Santiago Moreno Guillén, Andrea Antinori, Patrick Yeni, Barbara Wade, Margaret Johnson, Peter Shalit, Ramin Ebrahimi, Bethsheba Johnson, Ivan Walker & Shampa De-Oertel. (2015) Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial. The Patient - Patient-Centered Outcomes Research 8:3, pages 257-267.
Crossref
Crossref
Ting Ting Lee & Ian Paul Everall. 2015. International Encyclopedia of the Social & Behavioral Sciences. International Encyclopedia of the Social & Behavioral Sciences
488
494
.
Linda Beer & Jacek Skarbinski. (2014) Adherence to Antiretroviral Therapy Among HIV-Infected Adults in the United States. AIDS Education and Prevention 26:6, pages 521-537.
Crossref
Crossref
Jennifer A. Johnson & Paul E. Sax. (2014) Beginning Antiretroviral Therapy for Patients with HIV. Infectious Disease Clinics of North America 28:3, pages 421-438.
Crossref
Crossref
Christoph D. Spinner. (2014) Vor- und Nachteile in der modernen ART. MMW - Fortschritte der Medizin 156:S24, pages 29-33.
Crossref
Crossref
Krisda H. Chaiyachati, Osondu Ogbuoji, Matthew Price, Amitabh B. Suthar, Eyerusalem K. Negussie & Till Bärnighausen. (2014) Interventions to improve adherence to antiretroviral therapy. AIDS 28, pages S187-S204.
Crossref
Crossref